| everolimus / Generic mfg. |
2010-020305-32: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as first line treatment |
|
|
| Ongoing | 2 | 25 | Europe | Capsule, soft, Tablet, GLIVEC, CERTICAN | ISTITUTO NAZIONALE PER LA CURA TUMORI | patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation | | | | |
NCT01412515 / 2007-000974-22: A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma |
|
|
| Terminated | 2 | 11 | Europe | everolimus | Institut National de la Santé Et de la Recherche Médicale, France | Kaposi Sarcoma | 05/11 | 05/11 | | |
NCT01048723: Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas |
|
|
| Terminated | 2 | 2 | US | RAD001, everolimus | H. Lee Moffitt Cancer Center and Research Institute, Novartis | Sarcoma | 10/11 | 10/11 | | |
| Completed | 2 | 41 | RoW | RAD001, Everolimus | Asan Medical Center, Novartis | Soft Tissue Sarcomas, Bone Sarcomas | 01/13 | | | |
|
NCT01216839: Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas |
|
|
| Unknown status | 2 | 20 | RoW | Everolimus, Afinitor, RAD | Sidnei Epelman | Refractory or Relapsed RMS and Soft Tissue Sarcomas | 10/13 | 12/13 | | |
NCT01216826: Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma |
|
|
| Unknown status | 2 | 20 | RoW | Everolimus, Afinitor, RAD. | Sidnei Epelman | Refractory or Relapsed Osteosarcoma | 06/14 | 12/14 | | |
SERIO, NCT01804374: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma |
|
|
| Completed | 2 | 38 | Europe | Sorafenib, BAY 43-9006, Nexavar, Everolimus, RAD001, Afinitor, Certican | Italian Sarcoma Group | Metastatic Osteosarcoma, Relapsed Osteosarcoma | 12/14 | 12/14 | | |
|
2011-000561-12: study of the combination with sorafenib and everolimus in patients affected by non-resectable high-grade osteosarcoma. Studio sull\'associazione di sorafenib ed everolimus in pazienti affetti da osteosarcoma ad alto grado di malignita\' non operabile |
|
|
| Completed | 2 | 37 | Europe | NEXAVAR, NEXAVAR | ITALIAN SARCOMA GROUP, Bayer S.p.A. | Patients with high-grade Osteosarcoma, not resectable/metastatic, failing at least 2 different lines of standard tr4eatment for relapsed/metastatic disease Pazienti affetti da Osteosarcoma ad alto grado di malignita\' non resecabile/metastatico dopo fallimento di una o due linee terapeutiche standard per la malattia recidivata/metastatica | | 06/15 | | |
| Completed | 2 | 71 | Europe | Everolimus, RAD001 | Novartis Pharmaceuticals | Progressive Sarcoma | 05/17 | 05/17 | | |
NCT01661283: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors |
|
|
| Completed | 2 | 25 | US | everolimus, Afinitor, everolimus, bevacizumab, Avastin | Sarcoma Alliance for Research through Collaboration, Novartis Pharmaceuticals, Genentech, Inc., United States Department of Defense | Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma | 06/17 | 12/17 | | |
|
CHONRAD, NCT02008019: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas |
|
|
| Suspended | 2 | 57 | Europe | Everolimus 2.5 mg/day, Afinitor; Votubia; RAD-001, Everolimus 10 mg/day | Centre Leon Berard | Chondrosarcoma | 08/18 | 08/19 | | |
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
NCT03114527: Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) |
|
|
| Active, not recruiting | 2 | 48 | US | Ribociclib, LEE011, Everolimus, RAD001, Afinitor | Fox Chase Cancer Center | Soft Tissue Sarcoma | 06/24 | 12/24 | | |
NCT01281865: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma |
|
|
| Completed | 1b/2 | 14 | US | diagnostic laboratory biomarker analysis, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, imatinib mesylate, CGP 57148, Gleevec, Glivec | National Cancer Institute (NCI) | Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 10/13 | 10/13 | | |
|
NCT01275222: Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors |
|
|
| Completed | 1/2 | 117 | Europe, US | RAD001, everolimus, Imatinib 600mg/day (Glevec is the brand name for imatinib), STI571, Imatinib 800mg/day (Glevec is the brand name for imatinib) | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumors | 09/08 | 09/08 | | |
NCT03245151 / 2022-003736-77: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors |
|
|
| Completed | 1/2 | 64 | Canada, US | Lenvatinib, Everolimus | Eisai Inc., Merck Sharp & Dohme LLC | Recurrent and Refractory Solid Tumors | 09/22 | 09/22 | | |
